VIDEO: Strategies for simplifying ART regimens hold ‘considerable promise’
In recent years, “a great deal of interest” has been generated around simplifying ART regimens, according to Daniel Kuritzkes, MD, principal investigator of the AIDS Clinical Trials Group and chief of infectious diseases at Brigham and Women's Hospital and professor of medicine at Harvard Medical School.
Kuritzkes reviews the rationale for simplified regimens and the strategies being investigated, including implantable formulations, regimens with fewer medications and injectable agents. In particular, the combination of cabotegravir (ViiV Healthcare) and Edurant (rilpivirine, Janssen Therapeutics) is being studied as an injectable agent, and the combination of Tivicay (dolutegravir, ViiV Healthcare) and lamivudine is being tested as a way to decrease the number of medications in a regimen.
Simplified regimens would be an “enormous advantage,” according to Kuritzkes, and “a big step forward.”
“All of these approaches hold considerable promise,” he said.